Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
Definium Therapeutics' LSD therapy shows promise in easing anxiety in a late-stage trial.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 17.
Source diversity sample: Yahoo Finance · STAT · BioSpace · Endpoints News · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Definium Therapeutics announced that its LSD-based therapy demonstrated efficacy in reducing anxiety in a phase 3 trial. The positive results mark the second successful phase 3 trial for the company's psychedelic treatment. The trial's success has drawn attention to the broader field of psychedelic drug development, with investors and industry watchers focusing on upcoming catalysts from Definium and Compass Pathways.
The trial's outcome has sparked significant market reaction. Definium's stock, DFTX, is experiencing volatility as investors react to the trial data. The company's success in phase 3 trials positions it as a leader in the psychedelic therapeutics space.
The reporting does not yet specify the size of the trial or the exact nature of the anxiety disorders treated. The market reaction to the trial data is mixed, with some outlets noting the potential for a 'sea change' in anxiety treatment. The next phase 3 trial results and regulatory decisions will be crucial in determining the therapy's future.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Who reported it (6)
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder Yahoo Finance · 6h ago
- Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial STAT · 6h ago
- All eyes on psychedelic drugmakers as Definium, Compass near major catalysts BioSpace · 6h ago
- Definium’s LSD drug clears bar in first of two Phase 3 anxiety disorder trials Endpoints News · 6h ago
- DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data Yahoo Finance · 6h ago
- Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety Fierce Biotech · 6h ago
The obvious questions
What did Definium Therapeutics announce?
Definium Therapeutics announced that its LSD-based therapy showed efficacy in reducing anxiety in a phase 3 trial.
How has the market reacted to the trial results?
Definium's stock, DFTX, is experiencing volatility as investors react to the trial data.
What is the next step for Definium's LSD therapy?
The next phase 3 trial results and regulatory decisions will be crucial in determining the therapy's future.
Topics
Related trends
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake’s nanobody drug shows promise in treating psoriatic arthritis, but investors are cautious.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.